A federal district judge today upheld the Department of Health and Human Services’ (HHS) authority to preapprove 340B rebate models, [...] …
Category: Judicial
In their second emergency motion this month, a group of drugmakers is urging a federal appeals court to reject a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Three drugmakers and a drug industry tech firm are urging a federal appeals court to overturn a ruling that blocked [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Health technology company Kalderos has made waves in the 340B world in recent years after emerging as a key player [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
D.C. Federal District Court Dismisses Hospital Lawsuits Over J&J’s Controversial 340B Audit Requests
A Washington D.C. federal court this week threw out five hospital lawsuits challenging the Health Resources and Services Administration (HRSA) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A major North Carolina health system has sued insurers Aetna Health and Humana for allegedly underpaying for 340B drugs purchased [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Chicago-based pharmaceutical giant recently urged a federal court to block Colorado’s contract pharmacy access law—marking the first drug manufacturer [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A U.K.-based drugmaker recently asked a federal court to strike down Nebraska’s contract pharmacy access law, making it the latest [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A federal appellate court in Washington, D.C. is fast-tracking Novartis and Bristol Myers Squibb’s (BMS) appeal of a lower court [...] …